Current status of research on glucocorticoid-induced mouse models of osteoporosis
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [23]
  • | | | |
  • Comments
    Abstract:

    Glucocorticoid is a kind of steroids hormone secreted by the adrenal cortex zona fasciculate or artificially synthesized. It can mediate the synthesis and metabolism of carbohydrate, lipid and protein and has the function of inhibiting immune response and anti-inflammation, anti-toxic and anti-shock effects. However, long-term intake of corticostereoid hormone will result in bone loss, even severe osteoporosis, and increase the risk of fracture. As a result the research on the mechanisms of osteoporosis become more and more necessary. Now, according to the differences in establishment methods, there are three approaches, i.e. pellet implantation, drinking water and injection. As a result of the only partial similarity between different osteoporosis models and humans, there is a special application of each type of animal model of osteoporosis. The osteoporosis in glucocorticoid-induced model is mainly caused by modulating incretion, promoting bone absorption and inhibiting the osteoblast differentiation. In the meanwhile, compared with the other animal models, genes in mice are closer to humans, and they have many advantages in cost, gene and cell techniques. Therefore, glucocorticoid-induced mouse models of osteoporosis has a great significance in osteoporosis research. This article will review the establishment methods of glucocorticoid-induced mouse models of osteoporosis.

    Reference
    [1] Weinstein RS. Glucocorticoid-induced bone disease[J]. N Engl J Med, 2011, 365(1):62-70.
    [2] Liu J,Lu C,Wu X, et al.Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis[J]. Sci Rep, 2017, 7:41295.
    [3] Alten R,Wiebe E. Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches[J]. Neuroimmunomodulation, 2015, 22(1-2):83-88.
    [4] Altman A, Hochberg Z, Silbermann M. Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse[J]. Calcif Tissue Int,1992, 51(4):298-304.
    [5] Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids-potential mechanisms of their deleterious effects on bone[J]. J Clin Invest, 1998, 102(2):274-282.
    [6] Komori T. Animal models for osteoporosis[J]. Eur J Pharmacol, 2015, 759:287-294.
    [7] Thiele S, Baschant U, Rauch A, et al. Instructions for producing a mouse model of glucocorticoid-induced osteoporosis[J]. Bonekey Rep, 2014, 3:552.
    [8] Ersek A, Santo AI, Vattakuzhi Y, et al. Strain dependent differences in glucocorticoid-induced bone loss between C57BL/6J and CD-1 mice[J]. Sci Rep, 2016, 6:36513.
    [9] Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic non-infectious uveitis[J].Cochrane Database Syst Rev, 2016, 2:CD010469.
    [10] Yao W, Dai W, Jiang L, et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength[J]. Osteoporos Int, 2016, 27(1):283-294.
    [11] Gasparini SJ, Weber MC, Henneicke H, et al. Continuous corticosterone delivery via the drinking water or pellet implantation:a comparative study in mice[J]. Steroids, 2016, 116:76-82.
    [12] Karatsoreos IN, Bhagat SM, Bowles NP, et al. Endocrine and physiological changes in response to chronic corticosterone:a potential model of the metabolic syndrome in mouse[J]. Endocrinology, 2010, 151(5):2117-2127.
    [13] Fransson L, Franzen S, Rosengren V, et al. β-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome[J]. J Endocrinol, 2013, 219(3):231-241.
    [14] Shi J, Wang L, Zhang H, et al. Glucocorticoids:dose-related effects on osteoclast formation and function via reactive oxygen species and autophagy[J]. Bone, 2015, 79:222-232.
    [15] Li G, Bu J, Zhu Y, et al. Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9[J]. Int J Clin Exp Pathol, 2015, 8(12):15684-15695.
    [16] Lu Y, Zhang Z, Xiong X, et al. Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid X receptor[J]. Gastroenterology, 2012, 143(6):1630-1640.
    [17] Herrmann M, Henneicke H, Street J, et al. The challenge of continuous exogenous glucocorticoid administration in mice[J]. Steroids, 2009, 74(2):245-249.
    [18] Geraets SE, Gosens T. The intra-articular glucocorticoid injection; short-term success with potential side effects[J]. Ned Tijdschr Geneeskd, 2016, 160(0):D814.
    [19] 虞惊涛, 马信龙, 马剑雄. 骨质疏松动物模型评价方法[J]. 中华骨质疏松和骨矿盐疾病杂志, 2014, 7(1):5.
    [20] Liu SP, Liao EY, Chen J, et al. Effects of methylprednisolone on bone mineral density and microarchitecture of trabecular bones in rats with administration time and assessed by micro-computed tomography[J]. Acta Radiol, 2009, 50(1):93-100.
    [21] Akhter MP, Lappe JM, Davies KM, et al. Transmenopausal changes in the trabecular bone structure[J]. Bone, 2007, 41(1):111-116.
    [22] Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis[J]. Ann Lab Med, 2012. 32(2):105-112.
    [23] Jee WS, Yao W. Overview:animal models of osteopenia and osteoporosis[J]. J Musculoskelet Neuronal Interact, 2001, 1(3):193-207.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation
Share
Article Metrics
  • Abstract:2960
  • PDF: 3833
  • HTML: 0
  • Cited by: 0
History
  • Received:June 03,2017
  • Online: December 16,2017
Article QR Code